There is no single best antibiotic for bronchiectasis. The right choice depends on which bacteria are growing in your lungs, whether you’re treating a flare-up or trying to prevent one, and how severe your symptoms are. That’s why sputum cultures, where you cough up a sample for lab testing, are central to bronchiectasis care. Your treatment is matched to whatever organism the lab identifies and which drugs it responds to.
That said, clear patterns exist in how antibiotics are used across the different stages of this condition, and understanding them can help you make sense of your treatment plan.
Why Sputum Cultures Drive the Decision
Bronchiectasis involves permanently widened airways that trap mucus, creating an environment where bacteria thrive. The specific bacteria colonizing your lungs vary from person to person, and they change over time. The most common culprits include Haemophilus influenzae, Pseudomonas aeruginosa, and sometimes Klebsiella pneumoniae. Each responds to different antibiotics, so a drug that works well for one patient may be useless for another.
Guidelines from the British Thoracic Society and the European Respiratory Society recommend regular sputum cultures both when you’re feeling stable and during flare-ups. These cultures serve two purposes: they guide which antibiotic you receive, and they catch new infections early, particularly with Pseudomonas, which requires a more aggressive treatment approach. If your doctor hasn’t ordered a sputum culture recently, it’s worth asking about one, because empiric prescribing (guessing without lab data) becomes less reliable over time as resistance builds.
Treating Acute Exacerbations
When bronchiectasis flares up, with worsening cough, increased or discolored sputum, fever, or new breathlessness, the standard approach is a 14-day course of antibiotics. This is longer than what you’d take for a typical chest infection, and expert consensus across multiple guidelines consistently recommends this duration. A shorter course risks undertreating the infection in damaged airways where bacteria are harder to clear.
For most flare-ups, oral antibiotics guided by your most recent sputum culture results are the first step. If Pseudomonas aeruginosa is involved, treatment typically includes an oral fluoroquinolone or, when resistance is present, intravenous options. Combination antibiotics are generally reserved for patients with a history of Pseudomonas infection.
Intravenous antibiotics lasting 10 to 14 days come into play when flare-ups are severe, marked by signs like low oxygen levels, significant fever, or worsening breathlessness that doesn’t respond to oral treatment. Hospital admission for IV therapy may also be needed if you require intensive chest physiotherapy or if managing at home isn’t practical. In some cases, patients who are otherwise stable can receive IV antibiotics at home, particularly if they’re dealing with resistant Pseudomonas that doesn’t respond to oral drugs.
Long-Term Antibiotics to Prevent Flare-Ups
If you’re experiencing three or more exacerbations per year, long-term antibiotic therapy becomes a serious consideration. This is preventive, not curative. The goal is to reduce how often you get sick and how much lung damage accumulates over time. Two main strategies exist: oral macrolides and inhaled antibiotics.
Oral Macrolides
Azithromycin taken three times per week at a low dose (250 mg) is one of the most studied long-term options. Beyond killing bacteria, it also reduces inflammation in the airways, which is part of why it works. In clinical practice, this regimen has been shown to cut exacerbation frequency roughly in half, from about 0.81 episodes per month down to 0.41.
The trade-off is that oral macrolides carry systemic side effects that need monitoring. They can disrupt gut bacteria, and they pose risks for people with heart rhythm abnormalities, specifically a prolonged QT interval on an electrocardiogram. They can also affect hearing. Before starting long-term macrolide therapy, you’ll need an ECG and a sputum culture at minimum. If you have any existing hearing problems, a hearing test is also recommended. Importantly, macrolides should not be used alone if nontuberculous mycobacteria (a specific type of lung infection) show up in your cultures, because this can drive dangerous resistance.
Inhaled Antibiotics
For patients colonized with Pseudomonas aeruginosa, inhaled antibiotics deliver the drug directly to the lungs while minimizing side effects elsewhere in the body. The British Thoracic Society recommends inhaled colistin as the first-line choice for chronic Pseudomonas infection, with inhaled gentamicin as a second-line alternative.
Other inhaled options include tobramycin (available as both a liquid solution and a dry powder that’s faster to administer), aztreonam, levofloxacin, and amikacin. A newer dual-release ciprofloxacin formulation uses liposome technology to release the drug gradually, which reduces airway irritation during treatment. These inhaled therapies are particularly effective at reducing both the frequency and severity of flare-ups, with minimal systemic side effects compared to oral regimens.
When Pseudomonas Shows Up for the First Time
A first positive Pseudomonas culture is treated as an urgent event because early eradication can prevent chronic colonization, which is much harder to manage and is associated with worse outcomes. Current recommendations call for a susceptibility-guided oral fluoroquinolone or intravenous anti-pseudomonal antibiotics, sometimes followed by an inhaled antibiotic, for a total eradication regimen lasting six weeks to three months. In cystic fibrosis-related bronchiectasis, inhaled tobramycin (300 mg twice daily for 28 days) is strongly recommended as the eradication treatment, and similar principles often apply in non-CF bronchiectasis.
The Growing Problem of Resistance
Antibiotic resistance is a real and increasing concern in bronchiectasis. Among bronchiectasis patients globally, roughly 17% of Haemophilus influenzae isolates and 19% of Klebsiella pneumoniae isolates now show multidrug resistance. Pseudomonas resistance rates vary by geography, with particularly high levels in central and southern Europe.
This is one of the strongest arguments for sputum-guided prescribing rather than empiric treatment. Every course of antibiotics you take applies selective pressure on the bacteria in your lungs. Using the wrong drug, or using the right drug when you don’t actually need it, accelerates resistance without any benefit. Regular cultures help your care team stay ahead of resistance patterns specific to your lungs, ensuring each prescription counts.
Matching Treatment to Your Situation
The “best” antibiotic for bronchiectasis is ultimately the one that targets whatever is growing in your airways, at the right dose, for the right duration, through the right delivery method. For someone with infrequent flare-ups caused by Haemophilus, a 14-day oral course guided by sensitivity testing may be all that’s needed. For someone with chronic Pseudomonas and frequent exacerbations, the answer might be a combination of long-term inhaled colistin plus low-dose azithromycin three times a week.
If you’re not getting regular sputum cultures, or if you’re being prescribed the same antibiotic repeatedly without lab confirmation that it still works, that’s a gap worth addressing. The bacteria in bronchiectasis-affected lungs shift over time, and treatment needs to shift with them.